Adaptive Biotechnologies is trading 5.28% down at $22.95, after falling from the September 10 close of $24.23, with no clear catalyst identified for September 11.
- No fresh company-specific announcement, earnings release, regulatory action, or other clear catalyst was identified; the latest update concerns a Morgan Stanley conference scheduled earlier in September.
- S&P 500, Nasdaq Composite, and Dow futures were each higher pre-market.
- The cause remains unclear pending additional reporting.